Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)
Post# of 721
(Total Views: 224)
Posted On: 06/14/2018 6:26:42 PM
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Appeals to Investors with Slow Burn Rate, Model that Goes Beyond Cannabis Sector
- Chris Bunka, CEO of LXRP, in an interview with CFN Media Group, stated that his company’s cash flow is strengthening from licensing and R&D, with technology applicable to other sectors
- Bunka noted that LXRP’s 71 million share count is kept purposely low relative to others in the category, with its valuation growing by “close to 2,000 percent” over the past several years
- LXRP’s goal is to slow disease and make cannabis acceptable to the general population
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Chris Bunka said in a recent CFN Media Group interview that his company has gained in value and cash flow, purposely keeping its cash burn rate down and evaluating technology applications for both cannabis and other sectors (http://nnw.fm/N6LOm).
Bunka explained that LXRP is respecting its shareholders in terms of lowered spending and increasing its valuation, purposely maintaining its outstanding share count at relatively low levels. He said that LXRP is building its cash flow through licensing and R&D, as its technology can be used in other sectors besides cannabis. The company is focused on cannabinoid delivery R&D with its DehydraTECH™ technology, which enhances the performance of beneficial compounds in ingestible products, but it can be used across multiple categories, such as nicotine absorption. The result of all this, according to Bunka, is investors that are respected and a valuation of the company that has grown “by close to 2,000 percent’ in recent years.
Based in British Columbia, Canada, LXRP out-licenses its disruptive delivery technology that promotes healthier ingestion methods, resulting in lower dosing and higher effectiveness. LXRP holds a patent for oral delivery of all cannabinoids.
The company’s patented DehydraTECH™ is key to LXRP’s valuation. “We believe that infused foods should taste more like food and less like marijuana,” Bunka noted in the interview. “Our consumers find their coffee tastes a bit more like coffee and less like cannabis, and additionally notice that the cannabinoids take effect faster, and they feel a different type of effect than the typical edible. For medical patients who medicate often, that difference means a lot.”
Bunka explained that, within the tobacco and nicotine industry, recent lab tests have shown a 50 percent improvement in nicotine absorption into the bloodstream of rats with its technology, as compared to a control group. It found even higher percentage levels – 560 percent – of nicotine absorbed in brain tissue. It was a surprising result that might lead to development of cigarette smoking-cessation products by satisfying cravings for nicotine for extended periods of time. He said that these results, if replicated in human trials, could have a profound impact on treatment of cancer and brain tumors in the pharmaceutical and biotech sectors, making Lexaria’s technology a candidate for much more than cannabis applications.
The company’s patent portfolio is growing. It already has more than 40 patent applications or awards in more than 40 countries. Late last year, LXRP received its first U.S. patent on nicotine, ibuprofen and aspirin delivery, as well as cannabinoids. Bunka explained that the company is in the “active investigation phase” in the EU, Canada, China, Japan and India for more patents. “We’re filing new patent applications all the time,” he added.
For more information, visit the company’s website at www.LexariaEnergy.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Chris Bunka, CEO of LXRP, in an interview with CFN Media Group, stated that his company’s cash flow is strengthening from licensing and R&D, with technology applicable to other sectors
- Bunka noted that LXRP’s 71 million share count is kept purposely low relative to others in the category, with its valuation growing by “close to 2,000 percent” over the past several years
- LXRP’s goal is to slow disease and make cannabis acceptable to the general population
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Chris Bunka said in a recent CFN Media Group interview that his company has gained in value and cash flow, purposely keeping its cash burn rate down and evaluating technology applications for both cannabis and other sectors (http://nnw.fm/N6LOm).
Bunka explained that LXRP is respecting its shareholders in terms of lowered spending and increasing its valuation, purposely maintaining its outstanding share count at relatively low levels. He said that LXRP is building its cash flow through licensing and R&D, as its technology can be used in other sectors besides cannabis. The company is focused on cannabinoid delivery R&D with its DehydraTECH™ technology, which enhances the performance of beneficial compounds in ingestible products, but it can be used across multiple categories, such as nicotine absorption. The result of all this, according to Bunka, is investors that are respected and a valuation of the company that has grown “by close to 2,000 percent’ in recent years.
Based in British Columbia, Canada, LXRP out-licenses its disruptive delivery technology that promotes healthier ingestion methods, resulting in lower dosing and higher effectiveness. LXRP holds a patent for oral delivery of all cannabinoids.
The company’s patented DehydraTECH™ is key to LXRP’s valuation. “We believe that infused foods should taste more like food and less like marijuana,” Bunka noted in the interview. “Our consumers find their coffee tastes a bit more like coffee and less like cannabis, and additionally notice that the cannabinoids take effect faster, and they feel a different type of effect than the typical edible. For medical patients who medicate often, that difference means a lot.”
Bunka explained that, within the tobacco and nicotine industry, recent lab tests have shown a 50 percent improvement in nicotine absorption into the bloodstream of rats with its technology, as compared to a control group. It found even higher percentage levels – 560 percent – of nicotine absorbed in brain tissue. It was a surprising result that might lead to development of cigarette smoking-cessation products by satisfying cravings for nicotine for extended periods of time. He said that these results, if replicated in human trials, could have a profound impact on treatment of cancer and brain tumors in the pharmaceutical and biotech sectors, making Lexaria’s technology a candidate for much more than cannabis applications.
The company’s patent portfolio is growing. It already has more than 40 patent applications or awards in more than 40 countries. Late last year, LXRP received its first U.S. patent on nicotine, ibuprofen and aspirin delivery, as well as cannabinoids. Bunka explained that the company is in the “active investigation phase” in the EU, Canada, China, Japan and India for more patents. “We’re filing new patent applications all the time,” he added.
For more information, visit the company’s website at www.LexariaEnergy.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼